Clinical Trial Update: The Pharmacokinetics of LEO 90105 (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Extensive Psoriasis Vulgaris [Phase 1, Phase 2]

View source ↗

Summary

This update reports pharmacokinetic findings for the LEO 90105 combination (calcipotriol hydrate plus betamethasone dipropionate) in Japanese subjects with exte…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis Vulgaris

Drugs mentioned

• LEO 90105 (calcipotriol hydrate and betamethasone dipropionate)

Snippet

Sponsor: LEO Pharma | Conditions: Psoriasis Vulgaris | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2013-12-30